Contrast‐Induced Nephropathy
- 13 December 2007
- journal article
- review article
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 21 (1), 74-85
- https://doi.org/10.1111/j.1540-8183.2007.00318.x
Abstract
Radiological procedures utilizing intravascular iodinated contrast media are being widely applied for both diagnostic and therapeutic purposes and represent one of the main causes of contrast-induced nephropathy (CIN) and hospital-acquired renal failure. Due to the lack of any effective treatment, prevention of this iatrogenic disease, which is associated with significant in-hospital and long-term morbidity and mortality and increased costs, is the key strategy. However, prevention of CIN continues to elude clinicians and is a major concern during percutaneous coronary interventions (PCI), as patients undergoing these procedures often have multiple comorbidities. The purpose of this article is to examine the pathophysiology, risk factors, and clinical course of CIN, as well as the most recent studies dealing with its prevention and potential therapeutic interventions, especially during PCI.Keywords
This publication has 76 references indexed in Scilit:
- Trimetazidine in the prevention of contrast-induced nephropathy after coronary proceduresHeart, 2007
- Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL)Circulation, 2007
- Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patientsClinical Nephrology, 2006
- Effect of a Rapid Intra-Arterial Infusion of Dextrose 5% Prior to Coronary Angiography on Frequency of Contrast-Induced Nephropathy in High-Risk PatientsThe American Journal of Cardiology, 2006
- The potential role of statins in contrast nephropathyClinical Nephrology, 2004
- The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathyClinical Nephrology, 2004
- Impact of nephropathy after percutaneous coronary intervention and a method for risk stratificationThe American Journal of Cardiology, 2004
- Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathyThe American Journal of Cardiology, 2003
- Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrastCatheterization and Cardiovascular Interventions, 2003
- Hospital-acquired renal insufficiencyAmerican Journal of Kidney Diseases, 2002